Your browser doesn't support javascript.
loading
Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V.
Moyer, Bryan D; Murray, Justin K; Ligutti, Joseph; Andrews, Kristin; Favreau, Philippe; Jordan, John B; Lee, Josie H; Liu, Dong; Long, Jason; Sham, Kelvin; Shi, Licheng; Stöcklin, Reto; Wu, Bin; Yin, Ruoyuan; Yu, Violeta; Zou, Anruo; Biswas, Kaustav; Miranda, Les P.
Affiliation
  • Moyer BD; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Murray JK; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Ligutti J; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Andrews K; Molecular Engineering, Amgen Discovery Research, Cambridge, Massachusetts, United States of America.
  • Favreau P; Atheris Laboratories, CH Bernex, Geneva, Switzerland.
  • Jordan JB; Discovery Attribute Sciences, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Lee JH; Neuroscience, Amgen Discovery Research, Cambridge, Massachusetts, United States of America.
  • Liu D; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Long J; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Sham K; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Shi L; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Stöcklin R; Atheris Laboratories, CH Bernex, Geneva, Switzerland.
  • Wu B; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Yin R; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Yu V; Neuroscience, Amgen Discovery Research, Cambridge, Massachusetts, United States of America.
  • Zou A; Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Biswas K; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
  • Miranda LP; Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America.
PLoS One ; 13(5): e0196791, 2018.
Article in En | MEDLINE | ID: mdl-29723257
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptides / Spider Venoms / Sodium Channel Blockers / NAV1.7 Voltage-Gated Sodium Channel / Analgesics Type of study: Prognostic_studies Language: En Journal: PLoS One Year: 2018 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptides / Spider Venoms / Sodium Channel Blockers / NAV1.7 Voltage-Gated Sodium Channel / Analgesics Type of study: Prognostic_studies Language: En Journal: PLoS One Year: 2018 Type: Article Affiliation country: United States